Clinical trialNCT03113825CompletedPhase 2Interventional

Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

SponsorAvelas Biosciences, Inc.Enrollment92Breast Cancer FemaleCarcinoma BreastCarcinoma, Ductal, BreastPrimary Invasive Malignant Neoplasm of Female BreastStage I Breast CancerStage II Breast Cancer+1 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Phase 2, open-label study of AVB-620 in women with primary, nonrecurrent and nonmetastatic breast cancer undergoing surgery.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Steven Chen, MD, MBA
Avelas Biosciences, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Ucsd
San Diego, California, United States
Medstar Washington Hospital
Washington D.C., District of Columbia, United States
Mayo Clinic Jacksonville -- Center for Breast Health
Jacksonville, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Advocate Good Shepherd Hospital
Barrington, Illinois, United States
William Beaumont Hospital
Royal Oak, Michigan, United States
Unlv School of Medicine
Las Vegas, Nevada, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Montefiore Einstein Center for Cancer Care
The Bronx, New York, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Ohio State University, James Cancer Center
Columbus, Ohio, United States
Roper St. Francis Hospital
Charleston, South Carolina, United States
Swedish Cancer Institute
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AVB-620

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 5 Jul 2017
Primary completion: 8 Apr 2020
Completion: 18 Nov 2020
Last update posted: 11 Jun 2021
Registered enrollment: 92
Registry id: NCT03113825

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.